Ameriprise
VKTX icon

Ameriprise’s Viking Therapeutics VKTX Stock Holding History

Ameriprise’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.1M Buy
2,156,083
+477,338
+28% +$15.4M 0.02% 683
2026
Q1 		$54.6M Buy
1,678,745
+339,641
+25% +$10.9M 0.01% 828
2025
Q4 		$47.1M Sell
1,339,104
-753,736
-36% -$26.7M 0.01% 916
2025
Q3 		$55M Buy
2,092,840
+616,526
+42% +$18.4M 0.01% 832
2025
Q2 		$39.1M Buy
1,476,314
+58,191
+4% +$1.53M 0.01% 994
2025
Q1 		$34.2M Sell
1,418,123
-61,473
-4% -$1.94M 0.01% 1024
2024
Q4 		$59.5M Buy
1,479,596
+1,029,125
+228% +$58.7M 0.02% 751
2024
Q3 		$28.5M Buy
450,471
+168,338
+60% +$9.88M 0.01% 1133
2024
Q2 		$15M Sell
282,133
-168,281
-37% -$11M ﹤0.01% 1461
2024
Q1 		$36.8M Buy
450,414
+373,373
+485% +$16.6M 0.01% 948
2023
Q4 		$1.43M Buy
+77,041
New +$1.01M ﹤0.01% 3038
2022
Q1 		– Sell
-105,464
Closed -$485K – 4026
2021
Q4 		$485K Buy
+105,464
New +$591K ﹤0.01% 3538
2020
Q3 		– Sell
-47,973
Closed -$346K – 3792
2020
Q2 		$346K Sell
47,973
-34,784
-42% -$231K ﹤0.01% 3314
2020
Q1 		$387K Buy
82,757
+30,925
+60% +$190K ﹤0.01% 3217
2019
Q4 		$416K Buy
51,832
+24,133
+87% +$176K ﹤0.01% 3395
2019
Q3 		$191K Buy
27,699
+4,965
+22% +$36.9K ﹤0.01% 3565
2019
Q2 		$189K Buy
22,734
+8,656
+61% +$74K ﹤0.01% 3595
2019
Q1 		$140K Sell
14,078
-79,252
-85% -$663K ﹤0.01% 3607
2018
Q4 		$714K Buy
93,330
+11,558
+14% +$138K ﹤0.01% 3073
2018
Q3 		$1.42M Sell
81,772
-51,292
-39% -$610K ﹤0.01% 2939
2018
Q2 		$1.25M Buy
+133,064
New +$885K ﹤0.01% 2932

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ameriprise's VKTX Position: Q2 2026 in Review

Ameriprise increased its Viking Therapeutics (VKTX) stake by 28% in Q2 2026, buying an estimated $15.4M and bringing the position to 2,156,083 shares worth $84.1M. The position accounts for 0.02% of the portfolio, ranked #683.

Ameriprise first reported a position in VKTX in Q2 2018 and has held it in 21 quarters since. 434 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Ameriprise held 2,156,083 shares of Viking Therapeutics worth $84.1M as of Q2 2026.
  • Ameriprise bought 477,338 Viking Therapeutics shares in Q2 2026, an estimated $15.4M.
  • Viking Therapeutics made up 0.02% of Ameriprise's portfolio in Q2 2026, its #683 holding.
  • Ameriprise first reported a position in Viking Therapeutics in Q2 2018 and has held it in 21 quarters since.
  • 434 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.